Management of Chronic Spontaneous Urticaria Made Practical: What Every Clinician Should Know
Bibliographic record
Abstract
Despite its significant impact on quality of life, optimal management of chronic spontaneous urticaria remains challenging because of knowledge gaps regarding triggers, treatment response variability, and limited data for special populations. Second-generation H1-antihistamines are the first-line treatment and effective in approximately 50% of patients. For those who remain symptomatic, up-dosing up to fourfold is safe and recommended. However, prolonged ineffective antihistamine therapy should be avoided to prevent delayed disease control. In such cases, timely escalation to biologics, particularly omalizumab, is essential. Omalizumab remains the cornerstone of biologic therapy, offering rapid and sustained efficacy with an excellent safety profile. Personalized approaches involving dose escalation or interval adjustments further optimize outcomes. Cyclosporine A serves as an effective third-line option, particularly for autoimmune chronic spontaneous urticaria, but requires close monitoring because of dose-related adverse effects. Special considerations for children, pregnant individuals, and elderly people are discussed, reflecting the need for tailored approaches. Trigger avoidance, particularly nonsteroidal anti-inflammatory drugs, may aid management, although evidence is limited for many suspected exacerbating factors. Regular assessment of disease activity and control using validated tools such as the Urticaria Activity Score and Urticaria Control Test is essential for guiding treatment decisions and monitoring response. Updated international guidelines are anticipated to address emerging therapies and current knowledge gaps.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.012 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.002 | 0.001 |
| Science and technology studies | 0.002 | 0.002 |
| Scholarly communication | 0.004 | 0.011 |
| Open science | 0.002 | 0.002 |
| Research integrity | 0.008 | 0.012 |
| Insufficient payload (model declined to judge) | 0.008 | 0.005 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".